JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 62.5%

Neg 62.5% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.